drugset / Trial / NCT02099591
Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC) or at risk of OIC.
Timeline
- Start
- 2014-11
- Primary completion
- 2021-04
- Completion
- 2021-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naloxegol | Unknown | 12.5 mg | Oral |
| Subject | Naloxegol | Unknown | 25 mg | Oral |